SIGNIFICANT REDUCTION FROM BASELINE IN ITCH (ISS7)^1,2

Cupid-A

64% reduction with
DUPIXENT

VS

35% reduction with
placebo

(-10.44 [n=68] vs -6.02 [n=68] [P=0.0003])

Mean ISS7 at baseline
DUPIXENT: 16.25 (SD, 3.90); Placebo: 15.74 (SD, 4.11)

Cupid-C

48% reduction with
DUPIXENT

VS

33% reduction with
placebo

(-8.50 [n=73] vs -6.13 [n=75] [P=0.0270])

Mean ISS7 at baseline
DUPIXENT: 15.18 (SD, 3.59); Placebo: 14.96 (SD, 3.94)

SIGNIFICANT REDUCTION FROM BASELINE IN HIVES (HSS7)^1,2

Cupid-A

68% reduction with
DUPIXENT

VS

36% reduction with
placebo

(-10.54 [n=68] vs -5.85 [n=68] [P=0.0001])

Mean HSS7 at baseline
DUPIXENT: 15.85 (SD, 3.76); Placebo: 15.03 (SD, 4.81)

Cupid-C

46% reduction with
DUPIXENT

VS

31% reduction with
placebo

(-7.16 [n=73] vs -5.15 [n=75] [P=0.0450])

Mean HSS7 at baseline
DUPIXENT: 13.31 (SD, 4.43); Placebo: 12.90 (SD, 4.98)

SIGNIFICANT REDUCTION FROM BASELINE IN (UAS7)^1,2

Cupid-A

66% reduction with
DUPIXENT

VS

36% reduction with
placebo

(-20.99 [n=68] vs -11.95 [n=68] [P=0.0001])

Mean UAS7 at baseline
DUPIXENT: 32.10 (SD, 7.01); Placebo: 30.76 (SD, 8.19)

Cupid-C

48% reduction with
DUPIXENT

VS

32% reduction with
placebo

(-15.61 [n=73] vs -11.27 [n=75] [P=0.0324])

Mean UAS7 at baseline
DUPIXENT: 28.48 (SD, 7.10); Placebo: 27.86 (SD, 7.82)

Proportion Of Patients With Complete response
urticaria-free (uas7=0)^1,2

≈2.5x as many patients were urticaria-free vs placebo in CUPID-A
(32% with DUPIXENT [n=68] vs 13% with placebo [n=68] [P=0.0133])

≈1.8x as many patients were urticaria-free vs placebo in CUPID-C
(30% with DUPIXENT [n=73] vs 17% with placebo [n=75] [P=0.0165])

Significant reduction from baseline in itch (ISS7)^1,2

Cupid-A

64% reduction with
DUPIXENT

vs

35% reduction with
placebo

(-10.44 [n=68] vs -6.02 [n=68] [P=0.0003])

Mean ISS7 at baseline
DUPIXENT: 16.25 (SD, 3.90); Placebo:
15.74 (SD, 4.11)

Cupid-C

48% reduction with
DUPIXENT

vs

33% reduction with
placebo

(-8.50 [n=73] vs -6.13 [n=75] [P=0.0270])

Mean ISS7 at baseline
DUPIXENT: 15.18 (SD, 3.59); Placebo: 14.96 (SD,
3.94)

Significant reduction from baseline in hives (HSS7)^1,2

Cupid-A

68% reduction with
DUPIXENT

vs

36% reduction with
placebo

(-10.54 [n=68] vs -5.85 [n=68] [P=0.0001])

Mean HSS7 at baseline
DUPIXENT: 15.85 (SD, 3.76); Placebo: 15.03 (SD,
4.81)

Cupid-C

46% reduction with
DUPIXENT

vs

31% reduction with
placebo

(-7.16 [n=73] vs -5.15 [n=75] [P=0.0450])

Mean HSS7 at baseline
DUPIXENT: 13.31 (SD, 4.43); Placebo: 12.90 (SD,
4.98)

Significant reduction from baseline in (UAS7)^1,2

Cupid-A

66% reduction with
DUPIXENT

vs

36% reduction with
placebo

(-20.99 [n=68] vs -11.95 [n=68] [P=0.0001])

Mean UAS7 at baseline
DUPIXENT: 32.10 (SD, 7.01); Placebo: 30.76 (SD,
8.19)

Cupid-C

48% reduction with
DUPIXENT

vs

32% reduction with
placebo

(-15.61 [n=73] vs -11.27 [n=75] [P=0.0324])

Mean UAS7 at baseline
DUPIXENT: 28.48 (SD, 7.10); Placebo: 27.86 (SD,
7.82)

PROPORTION OF PATIENTS
WITH COMPLETE RESPONSE
URTICARIA-FREE (UAS7=0)^1,2

≈2.5x as many patients were
urticaria-free vs placebo in CUPID-A
(32% with DUPIXENT [n=68] vs
13% with placebo [n=68] [P=0.0133])

≈1.8x as many patients were
urticaria-free vs placebo in CUPID-C
(30% with DUPIXENT [n=73] vs
17% with placebo [n=75] [P=0.0165])

Trial design In
biologic-naive^a patients

Trial Designs: 284 adults and adolescents (12-17 years) with CSU who remained symptomatic despite H1 antihistamine treatment were randomized in CUPID-A and CUPID-C to DUPIXENT or placebo. All participants were anti-IgE treatment naive and remained on a stable H1 antihistamine dose. DUPIXENT-treated adults and adolescents ≥60 kg received 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.^1,2

Trial Efficacy Measures: Itch severity score (ISS) and hives severity score (HSS) are patient-reported assessments rated on a scale of 0 (none), 1 (mild itch/<20 hives), 2 (moderate itch/20 to 50 hives), and 3 (intense itch/>50 hives). ISS7 is the sum of the preceding 7 days’ itch scores, for a total ISS7 range of 0 to 21. HSS7 is the sum of the preceding 7 days’ hives scores, for a total HSS7 range of 0 to 21. Urticaria activity score (UAS) is the composite of ISS and HSS. UAS7 is the sum of ISS7 and HSS7 scores, for a total UAS7 range of 0 to 42.^1,2

HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; Q2W, once every 2 weeks; UAS7, urticaria activity score over 7 days.

^aBiologic-naive defined as no anti-IgE treatment.

Adverse reactions occurring in ≥2% of patients through Week 24¹ POOLED ACROSS CUPID STUDIES A, B, AND C^a
Adverse reaction	DUPIXENT 200/300 mg Q2W (n=195) %	Placebo (n=197) %
Injection site reaction^b	10	8

Rate of discontinuations due to
adverse events vs placebo

1.0% DUPIXENT

vs

2.5% PLACEBO

Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment¹

Safety profile studied
in >8900 patients
across us-approved
indications^1,c

^aPooled safety population from CUPID studies A, B, and C. CUPID-B was an identically designed study that enrolled 108 CSU patients (aged 12 years or older) who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy. The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.
^bInjection site reactions cluster includes injection site dermatitis, injection site erythema, injection site hematoma, injection site induration, injection site pain, injection site pruritus, injection site reaction, injection site swelling.
^cPatient total included patients in AD trials (SOLO 1, SOLO 2, CHRONOS, AD-1021, AD-1526, AD-1652, AD-1539, and AD-HAFT), asthma trials (DRI12544, QUEST, VENTURE, and VOYAGE), CRSwNP trials (SINUS-24 and SINUS-52), EoE trials (EoE-1 and EoE-2), PN trials (PRIME and PRIME2), COPD trials (BOREAS and NOTUS), and CSU trials (CUPID-A, CUPID-B, and CUPID-C).
AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; EoE, eosinophilic esophagitis; PN,
prurigo nodularis; Q2W, once every 2 weeks.

DUPIXENT Attributes And Considerations

NOT AN
IMMUNOSUPPRESSANT
OR A STEROID¹

NO INITIAL LAB
TESTING OR
ONGOING
LAB MONITORING

according to the
Prescribing Information¹

NO KNOWN DRUG‑TO‑DRUG INTERACTIONS¹

Not metabolized through
the liver or
excreted
through the kidneys

At-home
self-administration¹

Train patients and/or
caregivers on
proper
administration prior to use

NO boxed warning¹

Please see additional
Warnings and Precautions
in the Prescribing
Information and Important
Safety Information below.

Select important safety information

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized
urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs,
institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

One Regimen in Adults

One Regimen
in Adults

18+ YEARS

One dosage regimen
in adults
regardless
of weight

Initial loading dose:

600 mg 2 x 300 mg

Followed by:

300 mg Q2W 1 x 300 mg

Weight-tiered in adolescents^a

Weight-tiered
in adolescents^a

12 TO 17
YEARS

≥60 kg

Initial loading dose:

600 mg 2 x 300 mg

Followed by:

300 mg Q2W 1 x 300 mg

30 to <60 kg

Initial loading dose:

400 mg 2 x 200 mg

Followed by:

200 mg Q2W 1 x 200 mg

^a30 kg is equal to 66 lb; 60 kg is equal to 132 lb.

Dupixent® (dupilumab) 200mg or 300mg pre-filled pen and syringe for ages 12 years and up

Dupixent® (dupliumab) 200mg or 300mg pre-filled pen and syringe for ages 12 years and up

Available in a 200 mg
or 300 mg pre-filled pen

or pre-filled syringe
for subcutaneous
injection¹

Consider before injecting

DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance
of a healthcare provider¹

Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use, according to the Instructions for Use¹
Rotate injection site with each injection¹
A caregiver or patient 12 years of age and older may inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe or pre-filled pen. In children 12 years of age and older, it is recommended that DUPIXENT be given by or under the supervision of an adult¹
Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT¹

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Discover DUPIXENT MyWay Program benefits

*DUPIXENT MyWay* ENROLLMENT FORM
English Enrollment Form
Spanish Enrollment Form

Proportion Of Patients With Complete response
urticaria-free (uas7=0)^1,2

Significant reduction from baseline in itch (ISS7)^1,2

Significant reduction from baseline in hives (HSS7)^1,2

Significant reduction from baseline in (UAS7)^1,2

PROPORTION OF PATIENTS
WITH COMPLETE RESPONSE
URTICARIA-FREE (UAS7=0)^1,2

DUPIXENT Attributes And Considerations

NOT AN
IMMUNOSUPPRESSANT
OR A STEROID¹

NO INITIAL LAB
TESTING OR
ONGOING
LAB MONITORING

NO KNOWN DRUG‑TO‑DRUG INTERACTIONS¹

At-home
self-administration¹